Catalyst Pharmaceuticals (CPRX) EBIT Margin (2018 - 2026)

Catalyst Pharmaceuticals has reported EBIT Margin for 9 years, with the latest figure at 49.02% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin rose 421.0% year-over-year to 49.02%; the trailing twelve-month figure through Mar 2026 stood at 44.83% (up 156.0% YoY), and the FY2025 full-year result was 43.77%, up 409.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 49.02%, up from 40.52% in the prior quarter.
• The five-year high for EBIT Margin was 53.79% in Q2 2022, with the low at 36.21% in Q3 2023.
• Historically, EBIT Margin has averaged 38.74% across 5 years, with a median of 44.21% in 2024.
• Annual changes were most pronounced in 2023 — EBIT Margin sank 8007 bps — and 2024, when it surged 7577 bps.
• Catalyst Pharmaceuticals' EBIT Margin stood at 50.7% in 2022, then dropped by 26 bps to 37.71% in 2023, then rose by 18 bps to 44.31% in 2024, then fell by 9 bps to 40.52% in 2025, then gained by 21 bps to 49.02% in 2026.
• The last three EBIT Margin figures came in at 49.02% (Q1 2026), 40.52% (Q4 2025), and 44.66% (Q3 2025), per Business Quant data.